Skip to main navigation Investors & Media Investor Relations Overview Press Releases Corporate Deck Events & Presentations Press Kit Corporate Governance Financial Info Stock Info Analyst Coverage Investor Resources Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases – Nov 22, 2021 Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) READ MORE Events & Presentations Dec 1, 2021 8:50 AM EST Evercore ISI 4th Annual HealthCONx Conference READ MORE Info Overview Leadership Partners Healthcare Professionals Overview CRISPR/Cas9 What’s CRISPR/Cas9? How CRISPR/Cas9 Works Types of Edits Glossary Investors & Media Overview Press Releases Scientific Publications & Presentations Corporate Deck Events & Presentations Press Kit Programs & Pipeline Our Full-Spectrum Approach Pipeline In Vivo Therapies Ex Vivo Therapies Careers Overview Patients & Families Our Commitment Clinical Trials Community Perspective & Resources Expanded Access Policy © Intellia Therapeutics 2021 Cookie Policy Terms of Use Privacy Policy Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.